Cell and gene therapy are promising fields of biomedical research that focus on developing new treatments for a range of diseases by modifying cells and genes.

On one hand, a cell therapy involves the use of living cells as therapeutic agents to treat a variety of medical conditions, including cancer, immune disorders, and genetic diseases. The cells used in these therapies can be either from the patient's own body (autologous) or from a donor (allogeneic).

And, on the other hand, a gene therapy involves the use of genetic material, such as DNA or RNA, to treat or prevent disease by modifying the expression of genes. This can be done by replacing a missing or defective gene, introducing a new gene to help the body fight disease, or editing an existing gene to correct a mutation.

Currently, these two therapies are witnessing a technological transformation in the form of biomanufacturing 4.0.

Biomanufacturing 4.0 is a new approach to biomanufacturing that integrates advanced technologies, such as automation, artificial intelligence, machine learning, and big data analytics, to improve the efficiency, quality, and scalability of bioproduction processes. It is also known as "digital biomanufacturing" or "smart biomanufacturing."

In the context of biotechnology and life sciences, biomanufacturing refers to the production of biologics, such as vaccines, antibodies, proteins, and other biopharmaceuticals, using living cells or organisms.

Biomanufacturing 4.0 aims to optimize this process by leveraging digital technologies to better control and monitor the production process, reduce human error, and enable real-time data analysis and decision-making.

So, how exactly is this new revolution in cell and gene therapy going to impact the overall healthcare sector? To understand this, and more, BIS Research is conducting a webinar by involving some of the brightest minds from the field of biopharma and healthcare manufacturing.

Here are all the details:

Webinar Topic: Biomanufacturing 4.0 | A New Era in Cell and Gene Therapy Development

Agenda:

The main agenda of this webinar is to understand and explore the following:
•    Cell and Gene Therapy Biomanufacturing Market: Trends and Key Developments
•    Awaited Technologies in the Cell and Gene Therapy Development 
•    Regulatory Scenario – GMP/cGMP Guidelines
•    Biomanufacturing 4.0 - Adoption Scenario 
•    Conclusion and Future Outlook

Speakers:

Our eminent panellists for this webinar will be:

Dr. Likhesh Sharma – Dr. Likhesh Sharma comes with over 15 years of extensive experience in the field of biotechnology. His expertise ranges from protein engineering and characterization to cell analysis and cell therapy.

He earned his Ph.D. in Biophysics from the Indian Institute of Science, Bangalore, and an undergraduate honors degree from Delhi University. In his current role, he works closely with the industry and academia for the development of cell therapy in India while overseeing the South Asia region for Cytiva Cell Therapy as a product manager. 

Mario Novoa Belman – Mr. Mario Novoa Belman is an applications specialist and technical representative at Infors LATAM. He has more than 20 years of experience in the field of biotechnology. He is a biotechnologist engineer with a specialty in biological production and graduated from the Interdisciplinary Professional Unit of Biotechnology (UPIBI) of the National Polytechnic Institute (IPN).

He has extensive experience in the care of mammalian cell cultures, preservation and maintenance of genetically modified clones, generation of Standard Operating Procedures, formulation and sterilization of culture media, assembly, preparation and sterilization of bioreactors, and calibration and adjustment of equipment involved.

He was part of the team of experts and product specialists at Sartorius de México.

Akash Mhaskar – Akash Mhaskar is a principal analyst, healthcare, and leads the cell and gene therapy segment at BIS Research. He has about eight years of experience in healthcare market research and consulting. He comes with a rich experience in pharma and med-tech space, with specialization in competitive analysis, epidemiology modeling, and impact analysis.

Stuti Kandpal – Stuti Kandpal is working as a senior research associate with BIS Research in the cell and gene therapy/pharma team. She has done her master’s in biotechnology from Gautam Buddha University and has previously worked at Global Data Research Center (GDRC) in Hyderabad. She has an experience of about two years in market research.  

Why should you attend the webinar?

Apart from the fact that several of expert minds from the pharma industry will be a part of this extensive webinar, this will be a great opportunity for you learn about:

•    To Understand the Ecosystem of Cell and Gene Therapy Development
•    To Identify Factors Limiting the Adoption of Automation in Biomanufacturing
•    To Explore Upcoming Technologies in Cell and Gene Therapy Biomanufacturing
•    To Explore Market Opportunities in Different Regions
•    To Analyse the Futurist Scenario of the Cell and Gene Therapy Biomanufacturing Industry

Timing and Registration:

The webinar is going to take place on 28th Feb’23 at following global timings:

•    7:30 A.M. (EST)
•    12:30 P.M. (GMT)
•    6:00 PM (IST)

Register for the event today. Get an edge over your competitors by learning the evolution of Biomanufacturing 4.0.